U.S. flag

An official website of the United States government

CYP2C9*3 AND Piroxicam response

Germline classification:
drug response (1 submission)
Last evaluated:
Feb 11, 2019
Review status:
1 star out of maximum of 4 stars
criteria provided, single submitter
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000788100.3

Allele description

CYP2C9*3

Gene:
CYP2C9:cytochrome P450 family 2 subfamily C member 9 [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
10q23.33
Genomic location:
Preferred name:
CYP2C9*3
Other names:
NM_000771.3(CYP2C9):c.1075A>C (p.Ile359Leu); CYP2C9, ILE359LEU (rs1057910); 1075A>C
HGVS:
  • NC_000010.11:g.94981296A>C
  • NG_008385.2:g.48139A>C
  • NM_000771.4:c.1075A>CMANE SELECT
  • NP_000762.2:p.Ile359Leu
  • LRG_1195t1:c.1075A>C
  • LRG_1195:g.48139A>C
  • LRG_1195p1:p.Ile359Leu
  • NC_000010.10:g.96741053A>C
  • NG_008385.1:g.47639A>C
  • NM_000771.3:c.1075A>C
  • P11712:p.Ile359Leu
Protein change:
I359L; Ile359Leu
Links:
Medical Genetics Summaries: CYP2C9*3; PharmGKB Clinical Annotation: 655384720; PharmGKB Clinical Annotation: 769181841; PharmGKB Clinical Annotation: 827862258; PharmGKB Clinical Annotation: 981238437; UniProtKB: P11712#VAR_008345; OMIM: 601130.0001; dbSNP: rs1057910
NCBI 1000 Genomes Browser:
rs1057910
Molecular consequence:
  • NM_000771.4:c.1075A>C - missense variant - [Sequence Ontology: SO:0001583]

Condition(s)

Name:
Piroxicam response
Synonyms:
Feldene response
Identifiers:
MedGen: CN258188

Recent activity

Clear Turn Off Turn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Help
Submission AccessionSubmitterReview Status
(Assertion method)		Clinical Significance
(Last evaluated)		OriginMethodCitations
SCV000927098Medical Genetics Summaries
criteria provided, single submitter

(Medical Genetics Summaries: Piroxicam Therapy and CYP2C9 Genotype)		drug response
(Feb 11, 2019)
Condition: Piroxicam response
Drug reported used for: Pain		germlinecuration

PubMed (6)
[See all records that cite these PMIDs]

Citation Link

Help

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineyesnot providednot providednot providednot providednot providedcuration

Citations

PubMed

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?

Agúndez JA, García-Martín E, Martínez C.

Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20. doi: 10.1517/17425250902970998 . Review.

PubMed [citation]
PMID:
19422321

Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam.

Perini JA, Vianna-Jorge R, Brogliato AR, Suarez-Kurtz G.

Clin Pharmacol Ther. 2005 Oct;78(4):362-9.

PubMed [citation]
PMID:
16198655
See all PubMed Citations (6)

Details of each submission

From Medical Genetics Summaries, SCV000927098.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedcuration PubMed (6)

Description

Individuals with 2 decreased function alleles (CYP2C9 poor metabolizers) have reduced clearance of piroxicam. Because the standard recommended dose of piroxicam may cause abnormally high plasma levels, a dose reduction should be considered for these individuals.

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot providednot providednot providednot providednot provided

Last Updated: Aug 26, 2023